Localized Prostate Cancer Factor / Scatter Factor Levels in Patients with Clinically Predictive Value of Plasma Hepatocyte Growth
Amit K. Gupta,P. Karakiewicz,C. Roehrborn,Y. Lotan,A. Zlotta,S. Shariat
Abstract:Purpose: Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional cytokine that is involved in cancer growth, motility, invasion, and angiogenesis.We assessed whether preoperative plasma levels of HGF can enhance the accuracy of standard models for predicting pathologic features and clinical outcomes. Experimental Design:The study comprised 421consecutive patients treatedwith radical prostatectomy and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma. HGF/ SF was measured using a commercially available immunoassay. Multivariate logistic regression was used to assess the relationship between plasma HGF/SF and pathologic features.Multivariate Cox regression was used to predict disease recurrence. One thousand bootstrap replicates were created for internal validation and predictive accuracies were estimated for eachmodel. Results: Plasma HGF/SF levels were significantly elevated in patients with lymph node and/or seminal vesicle invasion (P < 0.0001and P = 0.007, respectively). Preoperative plasma HGF/SF level was an independent predictor of lymphnode invasion [odds ratio (OR) for every100 pg/mL increase in HGF/SF,1.82; 95% confidence interval (95%CI),1.33-2.49] and seminal vesicle invasion (OR,1.18; 95%CI,1.06-1.3). Addition of HGF/SF increased the accuracy of a basemodel that included standard preoperative variables for prediction of lymph node invasion by 6.7% (predictive accuracy, 98.4%). HGF/SF also independently predicted disease recurrence after surgery (hazard ratio,1.07; 95% CI,1.0-1.15). Conclusions: Preoperative plasma level of HGF/SF is an independent predictor of prostate cancer metastasis to lymph nodes and disease recurrence after surgery. Use of HGF may help in therapeutic decision-making and enrollment into clinical trials. Prostate cancer is the most common cancer and the second largest cause (9%) of cancer-related deaths among men in the Unites States. In 2007, it is estimated that there will be 218,890 new cases and 27,050 prostate cancer–related deaths (1). The advent of prostate-specific antigen (PSA) screening has led to a stage migration with a decrease in the number of patients presenting with advanced cancer. Despite this,f5% to 25% of patients with presumed localized disease have metastases to lymph nodes (2, 3) and up to 30% of patients experience disease recurrence after presumed curative treatment. Several prediction tools such as Kattan-nomograms, Partin tables, algorithms, and artificial neural networks have been developed to predict the presence of lymphatic metastases but none of them are sufficiently accurate and need supplementation with novel biomarkers to improve predictive accuracy (4). Accurate prediction of lymphatic metastases is extremely important because therapeutic decisions such as the choice of treatment (surgery versus radiation, neoadjuvant therapy) and decision to perform and the extent of pelvic lymphadenectomy are affected by this information. Identification of patients who are likely to fail definitive local therapy would be helpful for selecting patients best suited for local adjuvant radiation therapy or clinical trials of early systemic intervention. Therefore, there is a clear need for novel biomarkers that are specifically associated with biologically aggressive prostate cancer for improved staging and prognostication. Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional cytokine that modulates processes such as growth, adhesion, motility, matrix degradation, invasion, and angiogenesis (5). HGF/SF also stimulates mitosis, inhibits apoptosis, and induces morphogenesis in ductal epithelial cells (5). c-Met, a transmembrane receptor tyrosine kinase, is the only known receptor for HGF/SF. The same roles of HGF/SF in normal cellular processes also make it an important promoter of tumor growth, invasion, and metastasis. HGF/SF has been, for example, shown to augment the adherence of tumor cells to Imaging, Diagnosis, Prognosis Authors’ Affiliations: Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas; Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada; and Mount Sinai and Princess Margaret Hospitals, University of Toronto, Toronto, Ontario, Canada Received12/9/07; revised 4/22/08; accepted 5/6/08. Grant support: Departmental. The costs of publication of this article were defrayed in part by the payment of page charges.This article must therefore be hereby marked advertisement in accordance with18 U.S.C. Section1734 solely to indicate this fact. Requests for reprints: Shahrokh F. Shariat, Department of Urology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9110. Phone: 214-648-6707; Fax: 214-648-8786; E-mail: Shahrokh.Shariat@UTSouthwestern.edu. F2008 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-07-5110 www.aacrjournals.org Clin Cancer Res 2008;14(22) November15, 2008 7385 Research. on April 30, 2017. © 2008 American Association for Cancer clincancerres.aacrjournals.org Downloaded from the endothelium and enhance transmigration through extracellular matrix (6). Several studies have shown a relationship between serum and tissue concentration of HGF/SF with progression of several cancers such as gastric, breast, lung, and hypopharyngeal (7–11). In prostate cancer, however, the prognostic value of HGF/SF is not well studied. Studies have shown that HGF/SF levels are elevated in metastatic disease (12). However, whether HGF/SF can independently predict poor pathologic features or clinical outcomes is not known. In this study, we investigated the ability of preoperative plasma levels HGF/SF to predict adverse pathologic features and disease recurrence in patients treated with radical prostatectomy and bilateral lymphadenectomy for clinically localized disease. Materials and Methods Patient population. All studies were undertaken with the approval and oversight of the institutional review board. The study comprised 421 consecutive patients treated with radical prostatectomy and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma between July 1994 and November 1997. No patients were treated preoperatively with either hormonal or radiation therapy and none had secondary cancers. Serum total PSA (T-PSA) was measured by the Hybritech Tandem-R assay (Hybritech, Inc.). The median age was 61.1 y (range 39.4-75.5 y). The median T-PSA was 5.6 ng/mL (interquartile range, 3.7-8.6; range, 0.1-99.3). Staff pathologists, who were blinded to clinical outcomes, examined all prostatectomy specimens. Evaluation of the radical prostatectomy specimen was done as previously described in accordance with the guidelines of the College of American Pathologists (13, 14). We also assessed plasma HGF/SF levels in 64 consecutive healthy patients without cancer. These subjects were composed of men who participated in a prostate cancer screening program. They had no prior history of cancer or chronic disease, a normal digital rectal examination, and a T-PSA <2.0 ng/mL (15). The median age of the controls was 61.3 y (range 42.4-71.7 y). PlasmaHGF/SFmeasurements. Plasma sampleswere collected after a preoperative overnight fast on the morning of the day of surgery, at least 4 wk after transrectal guided needle biopsy of the prostate. Blood was collected into Vacutainer CPT (Becton Dickinson Vacutainer Systems) and centrifuged at room temperature for 20 min at 1,500 g . The top layer corresponding to plasma was decanted using sterile transfer pipettes. The plasma was immediately frozen and stored at -80jC in polypropylene cryopreservation vials (Nalgene, Nalge Nunc). For quantitative measurements of HGF/SF levels, we used a commercially available quantitative immunoassay (R&D Systems). Every sample was run in duplicate, and the mean was calculated for data analysis. Differences between the two measurements were minimal (intra-assay precision coefficients of variation, 7.8 F 9.6%). Postoperative follow-up. Patients generally were scheduled to have a digital rectal examination and serum T-PSA evaluation postoperatively every 3 mo for the 1st year, semiannually from the 2nd through the 5th years, and annually thereafter. Biochemical progression was defined as a sustained elevation, on two or more occasions, of T-PSA >0.2 ng/mL and was assigned to the date of the first value >0.2 ng/mL. Patients who received adjuvant radiation therapy before biochemical progression because of clinical or pathologic characteristics were considered to have disease progression from the date of the first T-PSA value >0.2 ng/mL. Statistical analysis. Age, T-PSA, and HGF/SF were not normally distributed. Thus, nonparametric tests were used for all data analysis. Biopsy and pathologic Gleason sums were grouped into three categories (2-6 versus 7 versus 8-10). The lowest category (Gleason sum 2-6) was used as the reference category. Spearman’s correlation (Rho) was used to assess the association between plasma HGF/SF level and continuous variables (i.e., age and T-PSA). The Wilcoxon-Mann-Whitney test and the Kruskal Wallis test were used to evaluate the association between HGF/SF and categorical clinicopathologic variables. Univariate and multivariate logistic regression analyses were done to assess the relationship between plasma HGF/SF levels and pathologic features. Logistic regression models were created using the ‘‘backward elimination method.’’ Hosmer and Lemeshow goodness-of-fit test was done to assess the fit of all the models and none of the models were found to have a poor fit. The assumption of linear association between the ln(odds) and predictors was assessed graphically and was satisfied